New combo shows promise in holding back prostate cancer
NCT ID NCT01314118
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 33 times
Summary
This study tested a combination of two drugs, abiraterone acetate and prednisone, in 131 men with advanced prostate cancer that had not yet shown up on scans. The goal was to see if the treatment could lower a key cancer marker (PSA) and delay the time until the cancer visibly grows. Participants continued their standard hormone therapy while taking the study drugs, and researchers monitored side effects and how long the benefits lasted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Homewood, Alabama, United States
-
Study site
Huntsville, Alabama, United States
-
Study site
Tucson, Arizona, United States
-
Study site
Los Angeles, California, United States
-
Study site
San Diego, California, United States
-
Study site
San Francisco, California, United States
-
Study site
Aurora, Colorado, United States
-
Study site
Denver, Colorado, United States
-
Study site
Aventura, Florida, United States
-
Study site
Orange City, Florida, United States
-
Study site
Atlanta, Georgia, United States
-
Study site
Evanston, Illinois, United States
-
Study site
Galesburg, Illinois, United States
-
Study site
Glenview, Illinois, United States
-
Study site
Melrose Park, Illinois, United States
-
Study site
Fort Wayne, Indiana, United States
-
Study site
Jeffersonville, Indiana, United States
-
Study site
New Orleans, Louisiana, United States
-
Study site
Baltimore, Maryland, United States
-
Study site
Rockville, Maryland, United States
-
Study site
Boston, Massachusetts, United States
-
Study site
Lansing, Michigan, United States
-
Study site
Omaha, Nebraska, United States
-
Study site
Lawrenceville, New Jersey, United States
-
Study site
Albany, New York, United States
-
Study site
Brooklyn, New York, United States
-
Study site
Buffalo, New York, United States
-
Study site
Garden City, New York, United States
-
Study site
New York, New York, United States
-
Study site
Poughkeepsie, New York, United States
-
Study site
Staten Island, New York, United States
-
Study site
Chapel Hill, North Carolina, United States
-
Study site
Raleigh, North Carolina, United States
-
Study site
Cincinnati, Ohio, United States
-
Study site
Cleveland, Ohio, United States
-
Study site
Lancaster, Pennsylvania, United States
-
Study site
Philadelphia, Pennsylvania, United States
-
Study site
Pittsburgh, Pennsylvania, United States
-
Study site
Greenville, South Carolina, United States
-
Study site
Myrtle Beach, South Carolina, United States
-
Study site
Nashville, Tennessee, United States
-
Study site
Arlington, Texas, United States
-
Study site
Houston, Texas, United States
-
Study site
Seattle, Washington, United States
-
Study site
Milwaukee, Wisconsin, United States
Conditions
Explore the condition pages connected to this study.